NEW YORK (GenomeWeb) – Stanford biosensing spin-out Nirmidas Biotech said this week that it has closed on a $2 million seed funding round.
According to the company, participants in the round include a leading venture capital fund, a life science angel investor, and the Stanford StartX Fund.
Nirmidas is developing a plasmonic gold chip platform for biomolecule detection and the detection of proteins in particular.
The technology comes out of the lab of Stanford researcher Hongjie Dai, who co-founded Nirmidas with CEO Meijie Tang, formerly a researcher at Lawrence Livermore National Laboratory. Currently operating with five employees, the company incorporated in September 2013 and began production of its initial research-focused chips in March this year.